Brain radiation: delay or start now? trial seeks better path for lung cancer patients
NCT ID NCT05987644
Summary
This study is for people with a specific type of advanced lung cancer (ALK-positive NSCLC) that has spread to the brain but isn't causing major symptoms. It's comparing two treatment strategies: taking the targeted drug alectinib alone versus taking alectinib plus a precise form of radiation to the brain (SRS) right away. The main goal is to see which approach better controls the brain tumors over 12 months while minimizing side effects like memory problems or brain swelling from radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
Contact
-
University of Colorado Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.